RemeGen - Public Comps and Valuation Multiples

RemeGen Overview

About RemeGen

RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat severe diseases such as autoimmune diseases, oncology, and ophthalmology. The company has its operations in China and the USA and derives the majority of its revenue from China.

Founded

2008

HQ

Employees

3.5K+

Website

remegen.com

Sectors

Biopharmaceuticals
BioTech

Financials

LTM Revenue $425M

LTM EBITDA -$14.0M

EV

$7.0B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

RemeGen Financials

As of November 2025, RemeGen reported last 12-month revenue of $425M and EBITDA of -$14.0M.

In the same period, RemeGen generated $359M in LTM gross profit and -$76.8M in net income.

See RemeGen valuation multiples based on analyst estimates

RemeGen P&L

In the most recent fiscal year, RemeGen reported revenue of $220M and EBITDA of -$141M.

RemeGen expects next 12-month revenue of XXX and NTM EBITDA of XXX

See RemeGen valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$425M	XXX	$220M	XXX	XXX	XXX
Gross Profit	$359M	XXX	$176M	XXX	XXX	XXX
Gross Margin	84%	XXX	80%	XXX	XXX	XXX
EBITDA	-$14.0M	XXX	-$141M	XXX	XXX	XXX
EBITDA Margin	-3%	XXX	-64%	XXX	XXX	XXX
EBIT	-$69.9M	XXX	-$176M	XXX	XXX	XXX
EBIT Margin	-16%	XXX	-80%	XXX	XXX	XXX
Net Profit	-$76.8M	XXX	-$189M	XXX	XXX	XXX
Net Margin	-18%	XXX	-86%	XXX	XXX	XXX
Net Debt	XXX	XXX	$232M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for RemeGen including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $425M. EBITDA for the last twelve months was -$14.0M. In the most recent fiscal year, RemeGen achieved $220M in revenue and -$141M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$425M	Analyst estimates available to subscribers	$220M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$359M	Analyst estimates available to subscribers	$176M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	84.4% gross margin	Analyst estimates available to subscribers	80.0% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	-$14.0M	Analyst estimates available to subscribers	-$141M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	-3.3% EBITDA margin	Analyst estimates available to subscribers	-64.1% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	-$69.9M	Analyst estimates available to subscribers	-$176M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	-16.4% EBIT margin	Analyst estimates available to subscribers	-80.2% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	-$76.8M	Analyst estimates available to subscribers	-$189M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	-18.1% net profit margin	Analyst estimates available to subscribers	-85.9% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$232M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for RemeGen

This financial data table provides comprehensive performance metrics for RemeGen, a company based in Hong Kong. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

RemeGen generated $425M in revenue over the last twelve months.
The company achieved -$14.0M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $359M.
Net income over the last twelve months reached -$76.8M.

Fiscal Year Performance

In the most recent fiscal year, RemeGen reported $220M in total revenue.
Fiscal year EBITDA was -$141M.
The company maintained a gross profit margin of 80.0% in the most recent fiscal year.
EBITDA margin for the fiscal year was -64.1%.
Net profit margin reached -85.9% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for RemeGen. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

RemeGen Stock Performance

RemeGen has current market cap of HKD 53.5B (or $6.9B), and EV of HKD 54.2B (or $7.0B).

Market Cap Evolution

RemeGen Stock Data

As of December 4, 2025, RemeGen's stock price is HKD 95 (or $12).

See RemeGen trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$7.0B	$6.9B	XXX	XXX	XXX	XXX	$-0.12

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

RemeGen Valuation Multiples

RemeGen's trades at 31.7x EV/Revenue multiple, and -49.5x EV/EBITDA.

See valuation multiples for RemeGen and 15K+ public comps

RemeGen Financial Valuation Multiples

As of December 4, 2025, RemeGen has market cap of $6.9B and EV of $7.0B.

Equity research analysts estimate RemeGen's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

RemeGen has a P/E ratio of -98.6x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$6.9B	XXX	$6.9B	XXX	XXX	XXX
EV (current)	$7.0B	XXX	$7.0B	XXX	XXX	XXX
EV/Revenue	18.0x	XXX	31.7x	XXX	XXX	XXX
EV/EBITDA	-545.9x	XXX	-49.5x	XXX	XXX	XXX
EV/EBIT	-109.7x	XXX	-39.5x	XXX	XXX	XXX
EV/Gross Profit	21.4x	XXX	n/a	XXX	XXX	XXX
P/E	-98.6x	XXX	-36.4x	XXX	XXX	XXX
EV/FCF	168.5x	XXX	-37.6x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get RemeGen Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

RemeGen Margins & Growth Rates

RemeGen's last 12 month revenue growth is 19%

RemeGen's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.

RemeGen's rule of 40 is -97% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

RemeGen's rule of X is 44% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for RemeGen and other 15K+ public comps

RemeGen Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	19%	XXX	45%	XXX	XXX	XXX
EBITDA Margin	-3%	XXX	-64%	XXX	XXX	XXX
EBITDA Growth	-370%	XXX	n/a	XXX	XXX	XXX
Rule of 40	-97%	XXX	-45%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	44%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	55%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	90%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	160%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial